GHSR1a inverse agonist for appetite suppression
Targeted lipolysis without insulin spike (glucagon arm)
agonist pocket: ortho · ▲ 0 · seed bank · 2026-05-05 08:07
🎁 Free tier: 3 design runs / 24h per IP. Each run
produces 4 candidates with full Compounding Lab Spec Sheets — no
signup needed.
Have an API key?
Desired effect
Drive hepatic and adipose lipolysis via glucagon receptor activation while sparing chronic hyperglycemia; tri-agonist or biased GCGR agonism.
Mechanism rationale
This metabolic-lane idea targets the mechanism described in the effect statement. Curated from the platform's 22-effect taxonomy.
Novelty basis
Underexplored in the academic + commercial literature, or addressed only by small-molecule programs. Peptide modality offers selectivity advantages.
Strategic value
Lane wedge: metabolic. Buyer archetypes include longevity biotechs, metabolic pharma, and performance/wellness brands depending on indication. Run Phase 4 and judge the public-stats output.
Design parameters
| Primary target | (matcher will resolve) |
|---|---|
| Secondary targets | — |
| Binding mode | agonist |
| Pocket mode | ortho |
| Modality hint | 20-40 aa with γ-Glu spacer + C18 fatty-acid (semaglutide-class) for once-weekly PK |